1.
Alhusseini N, Almuhanna Y, Alabduljabbar L, et al. International newborn screening: where are we in Saudi Arabia? <em>J Epidemiol Glob Health</em>. 2024;14(3):638-644.
2.
Odenwald B, Brockow I, Hanauer M, Lüders A, Nennstiel U. Is our newborn screening working well? A literature review of quality requirements for newborn blood spot screening (NBS) infrastructure and procedures. <em>Int J Neonatal Screen</em>. 2023;9(3):35.
3.
Akova İ, Kılıç E, Koşaroğlu NE. Evaluation of ten-year screening program results for neonatal metabolic and endocrine diseases: the case of Sivas, Turkey. <em>Turk J Public Health</em>. 2022;20(3):410-422.
4.
Wilson J, Jungner G. Principles and practice of screening for disease. world health organization. 1968. Available online: https://apps.who.int/iris/handle/10665/37650. Accessed June 11, 2024.
5.
Toktaş İ, Sarıbaş S, Canpolat S, Erdem Ö, Özbek MN. Evaluation of patients diagnosed with phenylketonuria and biotinidase deficiency by the newborn screening program: a ten-year retrospective study. <em>Turk J Pediatr</em>. 2022;64(6):985-992.
6.
Yenidoğan metabolik ve endokrin hastalık tarama programı (NTP). T.C. Sağlık Bakanlığı. 2023. Available at: https://hsgm.saglik.gov.tr/tr/tarama-programlari/ntp.html. Accessed June 11, 2024.
7.
Bayrak R, Ünsal A, Ünlü E. Examination of neonatal screening program results between 2015 and 2020 in Kırşehir Province. <em>Turk J Health Sci Res</em>. 2023;6(2):33-40.
8.
Fabie NAV, Pappas KB, Feldman GL. The current state of newborn screening in the United States. <em>Pediatr Clin North Am</em>. 2019;66(2):369-386.
9.
Öz E, Küçükkelepçe O, Almış H, Parlak ME, Kurt O. Evaluation of infant deaths during COVID-19 pandemic in Adıyaman, a southeastern province of Turkey. <em>Adıyaman Univ J Health Sci</em>. 2023;9(1):1-9.
10.
Yenidoğan metabolik ve endokrin hastalık tarama programı (NTP). T.C. Sağlık Bakanlığı program istatistikleri. 2023. Available at: https://hsgm.saglik.gov.tr/depo/birimler/cocuk-ergen-sagligi-db/Dokumanlar/Istatistikler/NTP.pdf. Accessed June 11, 2024.
11.
van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. <em>Nat Rev Dis Primers.</em> 2021;7:36.
12.
Hillert A, Anikster Y, Belanger-Quintana A, et al. The genetic landscape and epidemiology of phenylketonuria. <em>Am J Hum Genet</em>. 2020;107:234-250.
13.
2022 TÜİK aile istatistikleri. Available at: https://data.tuik.gov.tr/Bulten/Index?p=Istatistiklerle-Aile-2023-53784#:~:text=Akraba%20evlili%C4%9Fi%20oran%C4%B1%202023%20y%C4%B1l%C4%B1nda,%253%2C2%20oldu%C4%9Fu%20g%C3%B6r%C3%BCld%C3%BC. Accessed on: September 24th, 2024.
14.
Minamitani K. Newborn screening for congenital hypothyroidism in Japan. <em>Int J Neonatal Screen</em>. 2021;7(3):34.
15.
Aytaç N, Yüzügüllü DA, Gönültaş T, Altınsu T, Gür Ö, Çatak Ç. Evaluation of newborn screening results in Adana province for phenylketonuria, congenital hypothyroidism, and biotinidase deficiency in 2010-2011. <em>Sağlık ve Toplum</em>. 2016;26(3):37-43.
16.
Kazanasmaz H, Atas N, Karaca M. Specificity and sensitivity of biotinidase activity measured from dried blood spot by colorimetric method. <em>Ann Med Res</em>. 2019;26(10):2306-2311.
17.
Sarar M, Wafa E, Al-Aqeel AI, et al. Incidence of newborn screening disorders among 56632 infants in Central Saudi Arabia. <em>Saudi Med J</em>. 2020;41(7):703-708.
18.
2021 TÜİK doğum istatistikleri. Available at: https://data.tuik.gov.tr/Bulten/Index?p=Dogum-Istatistikleri-2021-45547. Accessed June 11, 2024.
19.
Funghini S, Tonin R, Malvagia S, et al. High frequency of biotinidase deficiency in Italian population identified by newborn screening. <em>Mol Genet Metab Rep</em>. 2020;25:100689.
20.
Maguolo A, Rodella G, Dianin A, et al. The experience of a regional center in Italy. <em>Front Pediatr</em>. 2021;9:661416.
21.
Özdemir A, Doğruel D. Newborn screening for cystic fibrosis in Mersin province: yearly assessment of the national program. <em>Turk Thorac J</em>. 2020;21(2):100.
22.
Scotet V, L’hostis C, Férec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. <em>Genes</em>. 2020;11(6):589.
23.
Eshragh N, Doan LV, Connelly KJ, et al. Outcome of newborn screening for congenital adrenal hyperplasia at two time points. <em>Horm Res Paediatr</em>. 2020;93(2):128-136.
24.
Verma J, Roy P, Thomas DC, et al. Newborn screening for congenital hypothyroidism, congenital adrenal hyperplasia, and glucose-6-phosphate dehydrogenase deficiency for improving health care in India. <em>J Pediatr Intensive Care</em>. 2020;9(01):40-44.
25.
Lind-Holst M, Bækvad-Hansen M, Berglund A, et al. Neonatal screening for congenital adrenal hyperplasia in Denmark: 10 years of experience. <em>Horm Res Paediatr</em>. 2022;95(1):35-42.
26.
Heather NL, Seneviratne SN, Webster D, et al. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013. <em>J Clin Endocrinol Metab</em>. 2015;100(3):1002-1008.
27.
2022 TÜİK doğum istatistikleri. Available at: https://data.tuik.gov.tr/Bulten/Index?p=Birth-Statistics-2022-49673. Accessed June 11, 2024.
28.
Lee BH, Deng S, Chiriboga CA, et al. Newborn screening for spinal muscular atrophy in New York state: clinical outcomes from the first 3 years. <em>Neurology</em>. 2022;99(14):e1527-e1537.
29.
Kimizu T, Ida S, Okamoto K, et al. Spinal muscular atrophy: diagnosis, incidence, and newborn screening in Japan. <em>Int J Neonatal Screen</em>. 2021;7(3):45.
30.
Vill K, Schwartz O, Blaschek A, et al. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years<em>. Orphanet J Rare Dis</em>. 2021;16(1):153.